- Home
- NLSP vs BRTX Comparison
NLSP vs BRTX Comparison
Compare NLSP & BRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NLSP
- BRTX
- Stock Information
- Founded
- NLSP 2015
- BRTX 1997
- Country
- NLSP Switzerland
- BRTX United States
- Employees
- NLSP N/A
- BRTX N/A
- Industry
- NLSP Biotechnology: Pharmaceutical Preparations
- BRTX Managed Health Care
- Sector
- NLSP Health Care
- BRTX Health Care
- Exchange
- NLSP Nasdaq
- BRTX Nasdaq
- Market Cap
- NLSP 12.4M
- BRTX 12.5M
- IPO Year
- NLSP 2021
- BRTX N/A
- Fundamental
- Price
- NLSP $2.17
- BRTX $1.51
- Analyst Decision
- NLSP
- BRTX
- Analyst Count
- NLSP 0
- BRTX 0
- Target Price
- NLSP N/A
- BRTX N/A
- AVG Volume (30 Days)
- NLSP 193.3K
- BRTX 99.6K
- Earning Date
- NLSP 10-17-2025
- BRTX 11-11-2025
- Dividend Yield
- NLSP N/A
- BRTX N/A
- EPS Growth
- NLSP N/A
- BRTX N/A
- EPS
- NLSP N/A
- BRTX N/A
- Revenue
- NLSP N/A
- BRTX $605,200.00
- Revenue This Year
- NLSP N/A
- BRTX $232.67
- Revenue Next Year
- NLSP N/A
- BRTX $52.92
- P/E Ratio
- NLSP N/A
- BRTX N/A
- Revenue Growth
- NLSP N/A
- BRTX 247.62
- 52 Week Low
- NLSP $1.30
- BRTX $1.21
- 52 Week High
- NLSP $6.97
- BRTX $2.55
- Technical
- Relative Strength Index (RSI)
- NLSP 49.81
- BRTX 42.94
- Support Level
- NLSP $1.88
- BRTX $1.56
- Resistance Level
- NLSP $2.02
- BRTX $1.63
- Average True Range (ATR)
- NLSP 0.13
- BRTX 0.10
- MACD
- NLSP -0.01
- BRTX -0.01
- Stochastic Oscillator
- NLSP 55.94
- BRTX 0.34
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd a clinical-stage biopharmaceutical company focused on the discovery and development of inventive therapies for patients with rare and complex CNS disorders with unmet medical needs. Its compound, mazindol, a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, in a proprietary ER formulation, is being developed for the treatment of narcolepsy, IH (follow-on indication), and potentially ADHD (back-up indication). Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.
About BRTX BioRestorative Therapies Inc. (NV)
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.